SCHEMBL7240551

SCHEMBL7240551

CCOc1ccnc(-c2cccc(N=C(N)NC(=O)OC(C)(C)C)c2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH2 P25021 7/20 0.43
HRH4 Q9H3N8 7/20 0.41
HRH3 Q9Y5N1 3/20 0.41
DRD2 P14416 1/20 0.41
DRD3 P35462 1/20 0.41
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
TTK P33981 1/20 0.39
MAPK8 P45983 1/20 0.39
ACACB O00763 1/20 0.38
ACACA Q13085 1/20 0.38
ITGB3 P05106 1/20 0.37
ITGB1 P05556 1/20 0.37
ITGAV P06756 1/20 0.37
ITGA2B P08514 1/20 0.37
ITGB5 P18084 1/20 0.37
HRH1 P35367 2/20 0.35
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7240547 1.00 HRH2 (0.43) HRH2HRH4HRH3DRD2DRD3
SCHEMBL7230300 0.91 ACACB (0.40) HRH2GAAMAPTTTKMAPK8
SCHEMBL7228914 0.90 SIGMAR1 (0.41) HRH2HRH4HRH3DRD2DRD3
SCHEMBL7229573 0.81 CCR1 (0.40) MAPTACACBACACALMNATP53
Hydrochloric Acid SCHEMBL7230311 0.79 ADRA2A (0.50) GAAMAPTTTKMAPK8TP53
SCHEMBL7847281 0.77 KMT2A (0.41) MAPTTTKMAPK8ACACBACACA
SCHEMBL7229865 0.77 CNR1 (0.43) ACACBACACA
SCHEMBL7847265 0.73 KDM4E (0.40) MAPTLMNANPC1TP53RAB9A
SCHEMBL7229054 0.73 MAPT (0.47) MAPTACACBACACALMNAHTT
SCHEMBL7847263 0.73 KDM4E (0.40) MAPTLMNANPC1TP53RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6521643-B1 Prevention and/or treatment of nitric oxide synthasey medi-ated diseases such as adult respiratory distress syndrome, myocarditis, synovitis, septic shock, diabetes, ulcerative colitis, cerebral infarction, osteoarthritis FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-02-18 US disclosed